Analytics-driven AAV development & manufacturing

A global footprint for best-in-class R&D and clinical support



Obtain a clear overview of the biochemical composition of each vector batch using less product.

**currently being implemented in QC for release testing*

A continuously evolving in-house analytics platform

Ascend has invested in an **industry-leading analytics platform with low volume sample volume methods**. We work to help preserve batch yields by consuming as little AAV as possible during analysis to ensure balanced AAV vector safety and potency for human use.

Our broad in-house analytics portfolio meticulously addresses concerns with data to de-risk your products. This portfolio includes residual DNA testing for plasmid and host cell DNA contamination; NGS and multiplex ddPCR analytics for residual DNA contamination and vector genome and transgene integrity.

Reliably quantifying full/empty capsid ratios impacts dosing, potency, and potentially immunogenicity and toxicity of AAV. **We can quantify empty/full capsid ratios on-site and quickly using low volumes** via mass photometry and several orthogonal methods, in addition to other low volume biophysical measurements such as capsid denaturation by nanoDSF, and subvisible particles.

Aim higher

ascend

ascend-adv.com business@ascend-adv.com

ADVANCED THERAPY MANUFACTURING SPECIALISTS